COMMUNIQUÉS West-GlobeNewswire
-
Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
09/11/2026 -
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
09/11/2026 -
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
09/11/2026 -
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
09/11/2026 -
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
09/11/2026 -
J-Star Holding Co., Ltd. Highlights U.S. Operational Progress with Delegation Visit from Global Tier 1 Carbon Fiber Manufacturer
09/11/2026 -
Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights
09/11/2026 -
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
09/11/2026 -
Transactions in connection with and conclusion of share buy-back program
09/11/2026 -
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
09/11/2026 -
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026 -
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026 -
GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
09/11/2026 -
GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027
09/11/2026 -
Essential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiency
09/11/2026 -
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
09/11/2026 -
Valneva annonce des résultats positifs de phase 2 pour son candidat vaccin tétravalent contre la shigellose S4V2
09/11/2026 -
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
09/11/2026 -
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
09/11/2026
Pages